147 related articles for article (PubMed ID: 37783755)
1. Histologic subtype-based evaluation of recurrence and survival outcomes in patients with adenocarcinoma of the ampulla of Vater.
Park SJ; Shin K; Hong TH; Lee SH; Kim IH; Kim Y; Lee M
Sci Rep; 2023 Oct; 13(1):16547. PubMed ID: 37783755
[TBL] [Abstract][Full Text] [Related]
2. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater.
Chang DK; Jamieson NB; Johns AL; Scarlett CJ; Pajic M; Chou A; Pinese M; Humphris JL; Jones MD; Toon C; Nagrial AM; Chantrill LA; Chin VT; Pinho AV; Rooman I; Cowley MJ; Wu J; Mead RS; Colvin EK; Samra JS; Corbo V; Bassi C; Falconi M; Lawlor RT; Crippa S; Sperandio N; Bersani S; Dickson EJ; Mohamed MA; Oien KA; Foulis AK; Musgrove EA; Sutherland RL; Kench JG; Carter CR; Gill AJ; Scarpa A; McKay CJ; Biankin AV
J Clin Oncol; 2013 Apr; 31(10):1348-56. PubMed ID: 23439753
[TBL] [Abstract][Full Text] [Related]
3. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma.
Schueneman A; Goggins M; Ensor J; Saka B; Neishaboori N; Lee S; Maitra A; Varadhachary G; Rezaee N; Wolfgang C; Adsay V; Wang H; Overman MJ
Br J Cancer; 2015 Jun; 113(1):64-8. PubMed ID: 25989273
[TBL] [Abstract][Full Text] [Related]
4. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
5. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
[TBL] [Abstract][Full Text] [Related]
6. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of ampulla of Vater cancer subtype classification based on immunohistochemical staining.
Kwon CH; Ahn JH; Seo HI; Kim DU; Han SY; Kim S; Lee NK; Hong SB; Park YM; Noh BG
World J Surg Oncol; 2024 Jan; 22(1):5. PubMed ID: 38167037
[TBL] [Abstract][Full Text] [Related]
8. Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater.
de Paiva Haddad LB; Patzina RA; Penteado S; Montagnini AL; da Cunha JE; Machado MC; Jukemura J
J Gastrointest Surg; 2010 Apr; 14(4):719-28. PubMed ID: 20107918
[TBL] [Abstract][Full Text] [Related]
9. Real-world efficacy and safety of capecitabine with oxaliplatin in patients with advanced adenocarcinoma of the ampulla of Vater.
Lee S; Park SJ; Shin K; Hong TH; Kim IH; Lee MA
BMC Cancer; 2024 May; 24(1):634. PubMed ID: 38783256
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
11. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Predictors for Intestinal and Pancreatobiliary Types of Adenocarcinoma of The Ampulla of Vater.
da Silveira Santos JPL; Machado CJ; Junior EP; Rodrigues JBSR; Vidigal PT; Resende V
J Gastrointest Surg; 2018 Jul; 22(7):1171-1178. PubMed ID: 29736668
[TBL] [Abstract][Full Text] [Related]
13. Intestinal and pancreatobiliary differentiation in periampullary carcinoma: the role of immunohistochemistry.
Kumari N; Prabha K; Singh RK; Baitha DK; Krishnani N
Hum Pathol; 2013 Oct; 44(10):2213-9. PubMed ID: 23834763
[TBL] [Abstract][Full Text] [Related]
14. Expression of the caudal-type homeodomain transcription factors CDX 1/2 and outcome in carcinomas of the ampulla of Vater.
Hansel DE; Maitra A; Lin JW; Goggins M; Argani P; Yeo CJ; Piantadosi S; Leach SD; Biankin AV
J Clin Oncol; 2005 Mar; 23(9):1811-8. PubMed ID: 15774774
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
Am J Surg Pathol; 2017 Jul; 41(7):865-876. PubMed ID: 28505002
[TBL] [Abstract][Full Text] [Related]
16. Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance.
Liu F; Shen D; Ma Y; Song Q; Wang H
J Surg Oncol; 2019 Mar; 119(3):295-302. PubMed ID: 30548547
[TBL] [Abstract][Full Text] [Related]
17. Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.
Kim MH; Jang M; Kim H; Lee WJ; Kang CM; Choi HJ
Cancer Immunol Immunother; 2019 Mar; 68(3):443-454. PubMed ID: 30604042
[TBL] [Abstract][Full Text] [Related]
18. Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival.
Williams JL; Chan CK; Toste PA; Elliott IA; Vasquez CR; Sunjaya DB; Swanson EA; Koo J; Hines OJ; Reber HA; Dawson DW; Donahue TR
JAMA Surg; 2017 Jan; 152(1):82-88. PubMed ID: 27732711
[TBL] [Abstract][Full Text] [Related]
19. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.
Perkins G; Svrcek M; Bouchet-Doumenq C; Voron T; Colussi O; Debove C; Merabtene F; Dumont S; Sauvanet A; Hammel P; Cros J; André T; Bachet JB; Bardier A; Douard R; Meatchi T; Peschaud F; Emile JF; Cojean-Zelek I; Laurent-Puig P; Taieb J
Br J Cancer; 2019 Apr; 120(7):697-702. PubMed ID: 30837681
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotyping of ampullary carcinomata allows for stratification of treatment specific subgroups.
Leo JM; Kalloger SE; Peixoto RD; Gale NS; Webber DL; Owen DA; Renouf D; Schaeffer DF
J Clin Pathol; 2016 May; 69(5):431-9. PubMed ID: 26500334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
